Breast Cancer | Specialty

FDA Grants Abemaciclib Priority Review for HR+/HER2- Breast Cancer

July 10th 2017

The FDA has granted a priority review to a new drug application for the CDK4/6 inhibitor abemaciclib as a treatment for patients with advanced hormone receptor–positive, HER2-negative breast cancer.

Lapatinib/Trastuzumab/AI Triplet Nearly Doubles PFS in HER2+/HR+ Metastatic Breast Cancer

July 7th 2017

The triplet combination of HER2-targeted therapy and an aromatase inhibitor improved progression-free survival by more than 5 months compared with the combination of trastuzumab (Herceptin) and an aromatase inhibitor in patients with HER2+/HR+ breast cancer.

Dr. Yardley on the Results of the APT and APHINITY Trials for HER2+ Breast Cancer

July 7th 2017

Denise Yardley, MD, senior investigator at the Sarah Cannon Research Institute, discusses the results of the APT and APHINITY trials for patients with HER2-positive breast cancer.

From Bench to Bedside: O'Shaughnessy Keeps Patients in Focus

July 2nd 2017

Joyce A. O'Shaughnessy, MD, whose research helped establish capecitabine and gemcitabine as treatments for patients with breast cancer, was honored in the Community Outreach/Education category with a 2016 Giants of Cancer Care® award, a program that OncLive® developed to recognize leaders in the field.

Dr. Brufsky on CDK 4/6 Inihibitors in Neoadjuvant Breast Cancer Treatment

June 29th 2017

Adam M. Brufsky, MD, PhD, professor of Medicine, associate chief of Hematology/Oncology, co-director of the Comprehensive Breast Care Center, associate director of Clinical Investigation, University of Pittsburgh, discusses CDK 4/6 inhibitors in neoadjuvant breast cancer treatment.

Dr. Freedman Discusses Dual HER2-Targeted Therapy in Breast Cancer

June 29th 2017

Rachel A. Freedman, MD, MPH, associate clinical director, Breast Oncology Center, Susan F. Smith Center for Women's Cancers, Dana-Farber Cancer Institute, senior physician, assistant professor of medicine, Harvard Medical School, discusses dual HER2-targeted therapies in breast cancer.

Abemaciclib Active in HR+/HER2- Breast Cancer Patients With Brain Mets

June 28th 2017

Preliminary evidence suggests that abemaciclib penetrated brain metastases and had antitumor activity in patients with hormone receptor-positive, HER2-negative metastatic breast cancer.

Study Offers Insight Into Age-Specific Breast, Ovarian Cancer Risk for BRCA-Positive Women

June 27th 2017

Researchers have yet to determine the degree to which harboring a BRCA1 or BRCA2 mutation raises a woman’s lifetime risk of developing breast and ovarian cancer.

Weight Loss Program Aims to Pinpoint Role of Obesity in Breast Cancer

June 27th 2017

Jennifer Ligibel, MD, describes the BWEL trial and the possible impact of weight loss intervention for patients with breast cancer.

Ribociclib Recommended for EU Approval in Frontline HR+/HER2- Breast Cancer

June 23rd 2017

The Committee for Medicinal Products for Human Use, a part of the European Medicines Agency, recommended approval of ribociclib (Kisqali) for use in combination with an aromatase inhibitor as a first-line treatment for postmenopausal women with hormone receptor-positive /HER2-negative locally advanced or metastatic breast cancer.

Dr. Burstein on the Follow-Up of APT Trial for HER2+ Breast Cancer

June 23rd 2017

Harold J. Burstein, MD, PhD, senior physician, associate professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the 7-year follow-up of the APT trial investigating adjuvant paclitaxel and trastuzumab (Herceptin) for node-negative HER2-positive breast cancer.

Dr. Yardley on the APHINITY Trial for HER2-Positive Breast Cancer

June 20th 2017

Denise Yardley, MD, senior investigator at the Sarah Cannon Research Institute, discusses the APHINITY trial investigating pertuzumab (Perjeta) for patients with adjuvant HER2-positive breast cancer.

Dr. Freedman on Preventing Brain Metastases in HER2+ Breast Cancer

June 20th 2017

Rachel A. Freedman, MD, MPH, associate clinical director, Breast Oncology Center, Susan F. Smith Center for Women's Cancers, Dana-Farber Cancer Institute, senior physician, assistant professor of medicine, Harvard Medical School, discusses preventing brain metastases in patients with HER2-positive breast cancer.

Dr. Tripathy Discusses Immunotherapy in HER2+ Breast Cancer

June 19th 2017

Debu Tripathy, MD, chair of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses immunotherapy in HER2-positive breast cancer.

Evolving Therapies in HR+ Metastatic Breast Cancer

June 16th 2017

Options With CDK4/6 in HR+ Metastatic Breast Cancer

June 16th 2017

Final Thoughts on Progress in Breast Cancer Research

June 16th 2017

Immunotherapy for Triple-Negative Breast Cancer

June 16th 2017

PARP Inhibitors for BRCA-Mutated TNBC

June 16th 2017

BRCA-Mutated Triple-Negative Breast Cancer

June 16th 2017